NIH-funded research Fellowship grant

Understanding how Staphylococcus aureus breaks down fatty acids

Official title: Characterization of the Staphylococcus aureus fatty acid degradation pathway

Funded at University of Kansas Medical Center · NIH-10821800 · Data updated 2026-11-12

This study is looking at how a common bacteria called Staphylococcus aureus breaks down fatty acids to survive, focusing on a special enzyme that might be really important in this process, which could help us find new ways to fight infections.

Quick facts

Grant typeFellowship grant
Study typeNIH-funded research
Funding institutionUniversity of Kansas Medical Center
NIH-funded
Lab location1 site (Kansas City, United States)
Project startSeptember 1, 2024
Project endAugust 31, 2028
Funding year2024
Award (this year)$37,460
NIH project number1F31AI181362-01
Project IDNIH-10821800 on NIH RePORTER

Who could benefit from this research

Could help

Patients with infections caused by Staphylococcus aureus, particularly those resistant to standard antibiotic treatments, would be ideal candidates to benefit from this research.

Less likely to help

Patients with infections caused by other types of bacteria or those not infected at all may not receive any benefit from this research.

What this research studies

This research investigates the mechanisms by which the bacteria Staphylococcus aureus degrades fatty acids, which are essential for its survival and function. The study focuses on identifying specific enzymes involved in this process, particularly a newly discovered crotonase enzyme that may play a critical role. By using advanced bioinformatics and genetic techniques, the research aims to clarify how these fatty acid degradation pathways operate and their implications for bacterial physiology. This knowledge could lead to better understanding of bacterial behavior and potential new targets for antibiotic development.

Why it matters

Potential benefit: If successful, this research could lead to new strategies for combating antibiotic-resistant Staphylococcus aureus infections.

How similar studies have gone: While the specific approach of targeting fatty acid degradation in Staphylococcus aureus is novel, similar research in other bacterial species has shown promise in understanding metabolic pathways and developing new treatments.

Where this research is happening

  • University of Kansas Medical Center
    Kansas City, United States
    Active

Researchers

  • Principal investigator: Menjivar, Cindy — University of Kansas Medical Center
  • Study coordinator: Menjivar, Cindy

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.